NCX 4040, a nitric oxide-donating aspirin, exerts anti-inflammatory effects through inhibition of I kappa B-alpha degradation in human monocytes
- PMID: 20065114
- DOI: 10.4049/jimmunol.0903107
NCX 4040, a nitric oxide-donating aspirin, exerts anti-inflammatory effects through inhibition of I kappa B-alpha degradation in human monocytes
Abstract
NO-donating aspirins consist of aspirin to which a NO-donating group is covalently linked via a spacer molecule. NCX 4040 and NCX 4016 are positional isomers with respect to the -CH(2)ONO(2) group (para and meta, respectively) on the benzene ring of the spacer. Because positional isomerism is critical for antitumor properties of NO-donating aspirins, we aimed to compare their anti-inflammatory effects with those of aspirin in vitro. Thus, we assessed their impacts on cyclooxygenase-2 activity (by measuring PGE(2) levels), protein expression, and cytokine generation(IL-1beta, IL-18, TNF-alpha, and IL-10) in human whole blood and isolated human monocytes stimulated with LPS. Interestingly, we found that micromolar concentrations of NCX 4040, but not NCX 4016 or aspirin, affected cyclooxygenase-2 expression and cytokine generation. We compared the effects of NCX 4040 with those of NCX 4016 or aspirin on IkappaB-alpha stabilization and proteasome activity in the LPS-stimulated human monocytic cell line THP1. Differently from aspirin and NCX 4016, NCX 4040, at a micromolar concentration range, inhibited IkappaB-alpha degradation. In fact, NCX 4040 caused concentration-dependent accumulation of IkappaB-alpha and its phosphorylated form. This effect was not reversed by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, an inhibitor of guanylyl cyclase, thus excluding the contribution of NO-dependent cGMP generation. In contrast, IkappaB-alpha accumulation by NCX 4040 may involve an inhibitory effect on proteasome functions. Indeed, NCX 4040 inhibited 20S proteasome activity when incubated with intact cells but not in the presence of cell lysate supernatants, thus suggesting an indirect inhibitory effect. In conclusion, NCX 4040 is an inhibitor of IkappaB-alpha degradation and proteasome function, and it should be taken into consideration for the development of novel anti-inflammatory and chemopreventive agents.
Similar articles
-
IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs.J Immunol. 2000 Nov 1;165(9):5245-54. doi: 10.4049/jimmunol.165.9.5245. J Immunol. 2000. PMID: 11046058
-
Effect of aspirin, paracetamol and their nitric oxide donating derivatives on exudate cytokine and PGE2 production in zymosan-induced air pouch inflammation in rats.Eur J Pharmacol. 2007 Apr 30;561(1-3):220-5. doi: 10.1016/j.ejphar.2007.01.033. Epub 2007 Feb 1. Eur J Pharmacol. 2007. PMID: 17320862
-
Comparative effects of aspirin and NO-releasing aspirins on differentiation, maturation and function of human monocyte-derived dendritic cells in vitro.Int Immunopharmacol. 2009 Jul;9(7-8):910-7. doi: 10.1016/j.intimp.2009.03.016. Epub 2009 Mar 31. Int Immunopharmacol. 2009. PMID: 19341823
-
NCX 4040, an NO-donating acetylsalicylic acid derivative: efficacy and mechanisms of action in cancer cells.Nitric Oxide. 2008 Sep;19(2):225-36. doi: 10.1016/j.niox.2008.04.007. Epub 2008 Apr 22. Nitric Oxide. 2008. PMID: 18472019 Review.
-
Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders.Cardiovasc Drug Rev. 2006 Summer;24(2):148-68. doi: 10.1111/j.1527-3466.2006.00148.x. Cardiovasc Drug Rev. 2006. PMID: 16961726 Review.
Cited by
-
Nitro aspirin (NCX4040) induces apoptosis in PC3 metastatic prostate cancer cells via hydrogen peroxide (H2O2)-mediated oxidative stress.Free Radic Biol Med. 2019 Nov 1;143:494-509. doi: 10.1016/j.freeradbiomed.2019.08.025. Epub 2019 Aug 22. Free Radic Biol Med. 2019. PMID: 31446057 Free PMC article.
-
Reconsidering the Role of Cyclooxygenase Inhibition in the Chemotherapeutic Value of NO-Releasing Aspirins for Lung Cancer.Molecules. 2019 May 18;24(10):1924. doi: 10.3390/molecules24101924. Molecules. 2019. PMID: 31109107 Free PMC article.
-
Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo.Front Pharmacol. 2020 Apr 2;11:374. doi: 10.3389/fphar.2020.00374. eCollection 2020. Front Pharmacol. 2020. PMID: 32317963 Free PMC article.
-
Mechanistic and pharmacological issues of aspirin as an anticancer agent.Pharmaceuticals (Basel). 2012 Dec 5;5(12):1346-71. doi: 10.3390/ph5121346. Pharmaceuticals (Basel). 2012. PMID: 24281340 Free PMC article.
-
Aspirin, cyclooxygenase inhibition and colorectal cancer.World J Gastrointest Pharmacol Ther. 2014 Feb 6;5(1):40-9. doi: 10.4292/wjgpt.v5.i1.40. World J Gastrointest Pharmacol Ther. 2014. PMID: 24605250 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous